Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Rebiopsy to Identify Mechanisms and Biomarkers of Tumor Cell Survival Following Systemic Therapy for Lung Cancer

NCT03042221 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT03042221
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03042221 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Rebiopsy to Identify Mechanisms and Biomarkers of Tumor Cell Survival Following Systemic Therapy for Lung Cancer
Lead sponsor
University of Colorado, Denver
Phase
Observational
Overall status
Recruiting
Start date
May 10, 2016
Completion date
September 30, 2027
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alk gene mutation, braf v600e, egfr gene mutation, non-small cell carcinoma of lung, tnm stage 4, non-small cell lung cancer, rose cluster 1